Related Experiment Video
Updated: Jun 6, 2026
14:51
Comprehensive Workflow of Mass Spectrometry-based Shotgun Proteomics of Tissue Samples
Published on: November 13, 2021
Consistency of a two clinical site sample collection: a proteomics study
Cedric Wiesner1, Charles Hannum, Karen Reckamp
1Facet Biotech, Redwood City, CA, USA.
Proteomics. Clinical Applications
|December 8, 2010
Summary
Clinical proteomic studies can reliably identify disease biomarkers from plasma samples collected at multiple sites. This multi-site approach using label-free 2-D-LC-MS (liquid chromatography-mass spectrometry) ensures reproducible results for biomarker discovery.
Area of Science:
- Biochemistry
- Clinical Proteomics
- Biomarker Discovery
Background:
- Clinical proteomic studies are crucial for identifying disease biomarkers.
- Ensuring reproducibility across different sample collection sites is a key challenge.
Purpose of the Study:
- To assess the feasibility of conducting reproducible clinical proteomic studies using samples from multiple independent sites.
- To determine if peptide profiling can detect reproducible disease-specific markers in plasma.
Main Methods:
- Label-free 2-D-LC-MS (liquid chromatography-mass spectrometry) was employed for peptide quantification.
- Analysis of tens of thousands of peptides from human plasma samples.
- Comparison of samples from two independent clinical sites.
Main Results:
- Reproducible detection of differentially expressed plasma proteins in advanced renal cancer patients compared to healthy controls.
- No systematic bias was observed related to sample collection or processing site.
- A support vector machine model achieved 88% sensitivity and 94% specificity in classifying disease samples.
Conclusions:
- Multi-site sample collection is viable for clinical proteomic studies.
- Label-free 2-D-LC-MS provides reproducible data suitable for reliable biomarker discovery.
- This methodology supports the development of robust diagnostic tools.
